10-Q · May 12, 2026
Avir Pharmaceuticals reported no revenue and an EPS of -$0.57 for Q1 2026, slightly missing expectations. The company is focused on advancing its clinical trials for HCV and HEV therapies, but continues to face…
Earnings analysis · 10-Q
AVIR earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
Atea reported diluted EPS of $(0.41), an improvement versus $(0.57) in the prior quarter and $(0.44) in the prior-year quarter, while the filing does not disclose revenue, margins or free cash flow in the provided text.…
Read full summary
Atea reported diluted EPS of $(0.41), an improvement versus $(0.57) in the prior quarter and $(0.44) in the prior-year quarter, while the filing does not disclose revenue, margins or free cash flow in the provided text. Liquidity was $219.5 million at June 30, 2026, against a six-month net loss of $78.4 million, $83.1 million of operating expenses and an accumulated deficit of $600.9 million. Clinical execution remains the principal catalyst, with C-FORWARD enrollment completed and topline results expected in early Q1 2027, but financing needs, China supply concentration and potential Gilead patent claims remain material risks.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.41
What stood out
-
EPS Improved Sequentially and Year Over Year
Diluted EPS was $(0.41), improving from $(0.57) in Q1 2026 and $(0.44) in Q2 2025 based on the reported quarterly history.
-
Operating Expenses Remain Controlled
Operating expenses were $83.1 million for the six months ended June 30, 2026, versus $180.9 million for full-year 2025, reflecting continued cost discipline.
-
Losses Continue as Pipeline Advances
The company reported a six-month net loss of $78.4 million and an accumulated deficit of $600.9 million as of June 30, 2026.
-
Substantial Liquidity Remains
Cash, cash equivalents and marketable securities totaled $219.5 million at June 30, 2026; the portfolio consisted of money-market funds, U.S. Treasuries and other short-term securities.
-
C-FORWARD Enrollment Completed
C-FORWARD enrollment was completed in June 2026, and management anticipates reporting topline results in early Q1 2027.
-
HCV Intellectual Property Expanded
A U.S. patent covering the bemnifosbuvir-and-ruzasvir HCV combination was issued on November 4, 2025, with an expected expiration in 2042; a morphic-form patent issued July 21, 2026 and expires March 31, 2043.
What to watch
-
Cash Burn and Future Financing Needs
Cash, cash equivalents and marketable securities were $219.5 million at June 30, 2026, while the company reported a six-month net loss of $78.4 million and expects operating losses for the foreseeable future, creating a continuing financing risk.
-
No Near-Term Product Revenue
The company has no products generating commercial revenue and states that it does not anticipate product-sales revenue for at least the next few years. Six-month operating expenses were $83.1 million.
-
Dependence on C-FORWARD Results
The lead HCV program remains dependent on C-FORWARD results expected in early Q1 2027; failure of the Phase 3 trial could prevent regulatory approval and commercialization.
-
Concentrated China Supply Chain
Ruzasvir has a sole active-pharmaceutical-ingredient supplier in China, and all regulatory starting-material suppliers for ruzasvir and bemnifosbuvir are located in China, exposing supply to geopolitical, tariff and disruption risks.
-
Potential Gilead Patent Conflict
Gilead patents issued in 2023 and 2024 purport to cover bemnifosbuvir, with stated expiration dates of June 15, 2028 and March 15, 2028; an adverse court ruling could require a license or constrain commercialization.
-
Prior Late-Stage Clinical Failure
The company disclosed that the SUNRISE-3 Phase 3 COVID-19 trial failed its primary endpoint in a monotherapy cohort of 2,221 high-risk patients, leading to discontinuation of bemnifosbuvir development for COVID-19.
Management's outlook
No quantitative revenue or EPS guidance was provided. Management anticipates reporting C-FORWARD topline results in early Q1 2027; no financial outlook was disclosed.
Earlier filings 4
10-K · March 5, 2026
Atea Pharmaceuticals is a late‑stage clinical biotech focused on orally administered nucleos(t)ide antivirals: a bemnifosbuvir + ruzasvir regimen for HCV (two Phase 3 programs) and AT‑587 for HEV (preclinical → Phase 1…
10-Q · November 12, 2025
Atea reported a Q3 net loss of $42,049 thousand (EPS -$0.53), larger than the prior-year quarter net loss of $31,151 thousand (EPS -$0.37). R&D spend rose to $38,347 thousand in the quarter while cash, cash equivalents…
10-Q · August 7, 2025
Atea reported a narrower Q2 net loss of $37,161 (EPS -$0.44) versus a loss of $40,522 (EPS -$0.48) in the prior-year quarter, driven by lower operating expenses. Liquidity remains strong with $379.7 million in cash,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.